I reported previously (Dec 2013) that VB-111 from Israel’s Vascular Biogenics (VBL Therapeutics) had been fast-tracked by the US FDA for the treatment of GBM – aggressive brain cancer.  Meanwhile, VBL has announced that VB-111’s Phase 2 trial for thyroid cancer was successful.

http://seekingalpha.com/pr/16747478-vbl-therapeutics-reports-full-data-vbminus-111-monotherapy-phase-2-trial-recurrent-thyroid